SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
Date of Report (Date of earliest event reported):
September 12, 2018
Yew Bio-Pharm Group, Inc.
(Exact name of registrant as specified in its
(State or other Jurisdiction
||(Commission File Number)
9460 Telstar Avenue, Suite 6
El Monte, California
|(Address of Principal Executive Offices)
Registrant’s telephone number, including
area code: (626)-401-9588
|(Former name or former address if changed since last report.)|
Check the appropriate box below if the Form
8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if
the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. ☐
SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION
REFORM ACT OF 1995
Information included in this Form 8-K may contain
forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act
of 1934, as amended (the "Exchange Act"). This information may involve known and unknown risks, uncertainties and other
factors which may cause actual results, performance or achievements of Yew Bio-Pharm Group, Inc. (herein referred to as the “Company”
or “Registrant”), to be materially different from future results, performance or achievements expressed or implied
by any forward-looking statements. Forward-looking statements, which involve assumptions and describe the Company’s future
plans, strategies and expectations, are generally identifiable by use of the words "may," "will," "should,"
"expect," "anticipate," "estimate," "believe," "intend" or "project"
or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are based
on assumptions that may be incorrect, and there can be no assurance that any projections or other expectations included in any
forward-looking statements will come to pass. The Company’s actual results could differ materially from those expressed or
implied by the forward-looking statements as a result of various factors. Except as required by applicable laws, the Company undertakes
no obligation to update publicly any forward-looking statements for any reason, even if new information becomes available or other
events occur in the future.
Section 7- Regulation FD
Item 7.01 Regulation FD Disclosure
On September 12, 2018, the
Company issued a press release announcing that it recently signed a Product Sales and Exclusive Distribution Agency Agreement (“Agency
Agreement”) to sell yew essential oil extracted from Taxus cuspidate. The Agency Agreement will continue for three years
until July, 2021. According to the Agency Agreement, in order to maintain exclusive agency rights, the agency agrees to purchase
no less than RMB 30,000,000 or about USD 4,300,000 worth of yew essential oil from the Company during the first year, and the purchase
amount will increase at least 30% year over year. A copy of the press release is filed as Exhibit 99.1 to this Current Report
on Form 8-K and is incorporated herein by reference.
This disclosure does not constitute an offer to sell, or the solicitation
to buy, any such security.
Financial Statements and Exhibits.
Pursuant to the Requirements of the Securities
Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the Undersigned hereunto duly authorized.
||Yew Bio-Pharm Group, Inc. |
|Date: September 12, 2018
||/s/ Zhiguo Wang|
|| Zhiguo Wang|
|| President & Chief Executive Officer|